PMC · DOI:10.3389/fimmu.2024.1365827·January 26, 2024
Corrigendum: Antimicrobial resistance in the COVID-19 landscape: is there an opportunity for anti-infective antibodies and antimicrobial peptides?
José M. Pérez de la Lastra, Uttpal Anand, Sergio González-Acosta, Manuel R. López, Abhijit Dey, Elza Bontempi, Antonio Morales delaNuez
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Diseases1
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDrug-Induced Adverse Reactions · SARS-CoV-2 and COVID-19 Research · Hepatitis B Virus Studies